Trial Profile
An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2020
Price :
$35
*
At a glance
- Drugs Paxalisib (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 08 Apr 2020 Results published in the Clinical Cancer Research
- 14 Jan 2020 Results published in the Clinical Cancer Research
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology